| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1586 | 2017 |
| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1512 | 2019 |
| Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study SM Domchek, S Postel-Vinay, SA Im, YH Park, JP Delord, A Italiano, ... The Lancet Oncology 21 (9), 1155-1164, 2020 | 329 | 2020 |
| A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) H Bonnefoi, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, ... Annals of Oncology 27 (5), 812-818, 2016 | 286 | 2016 |
| The official French guidelines to protect patients with cancer against SARS-CoV-2 infection B You, A Ravaud, A Canivet, G Ganem, P Giraud, R Guimbaud, ... The Lancet Oncology 21 (5), 619-621, 2020 | 230 | 2020 |
| A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors P Arnaud‐Coffin, D Maillet, HK Gan, JJ Stelmes, B You, S Dalle, J Péron International journal of cancer 145 (3), 639-648, 2019 | 202 | 2019 |
| Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? CS Chia, B You, E Decullier, D Vaudoyer, G Lorimier, K Abboud, ... Annals of surgical oncology 23, 1971-1979, 2016 | 172 | 2016 |
| Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs F Ranchon, G Salles, HM Späth, V Schwiertz, N Vantard, S Parat, ... BMC cancer 11, 1-10, 2011 | 161 | 2011 |
| Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial O Trédan, Q Wang, D Pissaloux, P Cassier, A de La Fouchardière, ... Annals of Oncology 30 (5), 757-765, 2019 | 149 | 2019 |
| Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis G Passot, B You, G Boschetti, J Fontaine, S Isaac, E Decullier, C Maurice, ... Annals of surgical oncology 21, 2608-2614, 2014 | 125 | 2014 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 115 | 2018 |
| Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis G Passot, D Vaudoyer, E Cotte, B You, S Isaac, FN Gilly, F Mohamed, ... Annals of surgery 256 (1), 125-129, 2012 | 113 | 2012 |
| Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review J Péron, D Maillet, HK Gan, EX Chen, B You Journal of Clinical Oncology 31 (31), 3957-3963, 2013 | 109 | 2013 |
| Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer HK Gan, B You, GR Pond, EX Chen Journal of the National Cancer Institute 104 (8), 590-598, 2012 | 108 | 2012 |
| Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial T Bachelot, T Filleron, I Bieche, M Arnedos, M Campone, F Dalenc, ... Nature Medicine 27 (2), 250-255, 2021 | 99 | 2021 |
| Inclusion of elderly patients in oncology clinical trials O Le Saux, C Falandry, HK Gan, B You, G Freyer, J Peron Annals of Oncology 27 (9), 1799-1804, 2016 | 98 | 2016 |
| Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review J Peron, GR Pond, HK Gan, EX Chen, R Almufti, D Maillet, B You Journal of the National Cancer Institute 104 (13), 982-989, 2012 | 97 | 2012 |
| Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease C Lok, N van Trommel, L Massuger, F Golfier, M Seckl, MH Abreu, J Attia, ... European Journal of Cancer 130, 228-240, 2020 | 88 | 2020 |
| Mortality rate of gestational trophoblastic neoplasia with a FIGO score of≥ 13 PA Bolze, C Riedl, J Massardier, JP Lotz, B You, AM Schott, T Hajri, ... American journal of obstetrics and gynecology 214 (3), 390. e1-390. e8, 2016 | 87 | 2016 |
| PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes PA Bolze, S Patrier, J Massardier, T Hajri, F Abbas, AM Schott, F Allias, ... International Journal of Gynecologic Cancer 27 (3), 2017 | 84 | 2017 |
Tod MFaculty of Pharmacy, University Lyon 1, FranceAdresse e-mail validée de univ-lyon1.fr
